ClinicalTrials.gg
CompletedNCT07722585Updated Oct 19, 2026

A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body

A Phase 1 interventional study of Nurandociguat (BAY3283142) old tablet - SD and Nurandociguat (BAY3283142) new tablet - SD in Chronic Kidney Disease, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Bayer · Phase 1, Interventional, and Other

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
29th of 32
16 · median 98
Started
2026
with 3 others
Phase 1
12 of 49
none open now
Registered
48th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 29th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 1, and was the 48th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 58 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

Researchers conduct this clinical study to learn more about a new tablet of a medicine called nurandociguat. Nurandociguat is being developed as a possible treatment for people with chronic kidney disease (CKD) which is a long-term condition in which the ability of the kidneys to properly function decreases over time. It is often caused by high blood glucose levels.

The main purposes of the study are

  • To learn how the new nurandociguat tablet is absorbed and processed in the body (which is also known as "pharmacokinetics [PK]" measurement) compared to an old tablet when taken without food.
  • To learn how food affects the way the new tablet is absorbed and processed in the body when taken with a high-fat, high-calorie meal (like a big breakfast).

To do this, researchers will take blood samples from the participants and measure:

  • Maximum observed concentration (Cmax): the highest concentration of nurandociguat in participants' plasma
  • Area under the concentration time curve (AUC): the total amount of nurandociguat in participants' plasma over time Another purpose of this study is to learn how safe the new nurandociguat tablet is. Therefore researchers will monitor the number of participants who experience medical problems during this study. These medical problems are called adverse events.

Only healthy participants are taking part in this study. During the study, participants will receive 2 different types of nurandociguat tablets. These include the newly developed tablet and an existing tablet that has already been used in previous clinical studies. Each participant will receive 3 different treatments:

  • Treatment A: Nurandociguat old tablet, taken without food
  • Treatment B: Nurandociguat new tablet, taken without food
  • Treatment C: Nurandociguat new tablet, taken with food Researchers have proposed 5 optional dosing schemes for this clinical study, however only one scheme will be selected based on the findings from an ongoing clinical study. Afterwards, the study will start.
  • For Optional Scheme 1-3, each participant will receive the three treatments A, B, and C, one at a time, in a different order for each participant with a break of at least 7 days between treatments.
  • The Optional Schemes 4-5 follow a fixed sequence design. Each participant will first receive the nurandociguat new tablet formulation at a lower dose for 7 days, then receive the higher dose for in total 11 days. The higher dose will be administered for 5 days using the old tablet formulation followed by 6 days using the new tablet formulation. PK measurement will be assessed after 5 days of treatment with the old tablet formulation (without food), after 5 days of treatment with the new tablet formulation (without food) and after 6 days of treatment with the new tablet formulation (with food).

The researchers will closely monitor and manage any medical problems that the participants may have during the study.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 58 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs (blood pressure and heart rate), (ECG), body temperature, and laboratory tests.
  • (BMI) within the range 18.0 and 29.9 kg/m\^2 (inclusive).
  • Body weight above or equal 60 kg.
  • Male and female.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study interventions will not be normal.
  • Acute diarrhea or constipation within 14 days before the first intake of study intervention.
  • Regular use of medicines within the last 14 days before the first study intervention administration.
  • Special diets preventing the participants from eating the standard meals during the study.
  • Participant is unable or unwilling to comply with study restrictions.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Optional Scheme 1-3: Treatment A-B-C

    Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Wash-out between treatments will be at least 7 days after last study drug administration.

    Drug: Nurandociguat (BAY3283142) old tablet - SD · Drug: Nurandociguat (BAY3283142) new tablet - SD

  • Experimental
    Optional Scheme 1-3: Treatment A-C-B

    Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment B: Single dose of nurandociguat new tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration.

    Drug: Nurandociguat (BAY3283142) old tablet - SD · Drug: Nurandociguat (BAY3283142) new tablet - SD

  • Experimental
    Optional Scheme 1-3: Treatment B-A-C

    Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Wash-out between treatments will be at least 7 days after last study drug administration.

    Drug: Nurandociguat (BAY3283142) old tablet - SD · Drug: Nurandociguat (BAY3283142) new tablet - SD

  • Experimental
    Optional Scheme 1-3: Treatment B-C-A

    Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment A: Single dose of nurandociguat old tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration.

    Drug: Nurandociguat (BAY3283142) old tablet - SD · Drug: Nurandociguat (BAY3283142) new tablet - SD

  • Experimental
    Optional Scheme 1-3: Treatment C-A-B

    Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment B: Single dose of nurandociguat new tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration.

    Drug: Nurandociguat (BAY3283142) old tablet - SD · Drug: Nurandociguat (BAY3283142) new tablet - SD

  • Experimental
    Optional Scheme 1-3: Treatment C-B-A

    Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment A: Single dose of nurandociguat old tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration.

    Drug: Nurandociguat (BAY3283142) old tablet - SD · Drug: Nurandociguat (BAY3283142) new tablet - SD

  • Experimental
    Optional Scheme 4-5

    Participants will receive nurandociguat new tablet for 7 days at a lower starting dose. Afterwards, there will be up titration to a higher dose for 11 days (nurandociguat old tablet for 5 days followed by PK analysis of old tablet formulation without food at steady state after 5 days; nurandociguat new tablet for 6 days followed by PK analysis of new tablet formulation without food at steady state after 5 days and with food after 6 days).

    Drug: Nurandociguat (BAY3283142) old tablet · Drug: Nurandociguat (BAY3283142) new tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Optional scheme 1-3 - Cmax for nurandociguat

    Cmax=Maximum observed concentration

    Time frame: 0-72 hours post dose

  2. Optional scheme 1-3 - AUC for nurandociguat

    AUC=Area under the concentration time curve

    Time frame: 0-72 hours post dose

  3. Optional scheme 4 and 5 - Cmax,md for nurandociguat

    Cmax,md=Cmax after multiple dosing

    Time frame: 0-24 hours post dose

  4. Optional scheme 4 and 5 - AUCt,md for nurandociguat

    AUCt,md=AUC after multiple dosing. t (Tau)=24 hours.

    Time frame: 0-24 hours post dose

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: From the first dose of study intervention up to 7 days after end of treatment with study intervention

07

Study locations

1 site
  • CRS Clinical Research Services Berlin GmbH
    Berlin, 13627, Germany
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Oct 2026, 2 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 23, 2026
StartActual
Jul 28, 2026
Primary completionActual
Oct 12, 2026
CompletionActual
Oct 12, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Primary completion
Oct 7, 2026→Oct 12, 2026 (actual)
Oct 19, 2026
Study completion
Oct 7, 2026→Oct 12, 2026 (actual)
Oct 19, 2026
Enrollment
18 (estimated)→16 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Primary completion Oct 7, 2026→Oct 12, 2026 (now actual)
    Study completion Oct 7, 2026→Oct 12, 2026 (now actual)
    Enrollment 18 (estimated)→16 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07722585
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Jul 28, 2026
Primary completion
Oct 12, 2026
Completion
Oct 12, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nurandociguat

Start the discussion